HSP90 expression is associated with outcome in pulmonary carcinoid tumor patients.

Pulmonary carcinoids (PC) gene expression heat-shock protein 90 (HSP90) immunohistochemistry

Journal

Translational lung cancer research
ISSN: 2218-6751
Titre abrégé: Transl Lung Cancer Res
Pays: China
ID NLM: 101646875

Informations de publication

Date de publication:
28 Sep 2023
Historique:
received: 11 05 2023
accepted: 18 08 2023
medline: 19 10 2023
pubmed: 19 10 2023
entrez: 19 10 2023
Statut: ppublish

Résumé

Pulmonary carcinoids (PCs) are rare tumors that account for <2% of all lung cancer cases. Patients who undergo resection for PC tumors generally have a favorable prognosis, but there is a risk for late recurrence and distant metastasis. The objective of this study was to identify biomarkers for PC tumors using RNA sequencing and immunohistochemistry. A total of 128 formalin-fixed, paraffin-embedded PC tumor samples from patients surgically treated at Helsinki University Hospital between 1990 and 2013 were analyzed in the study. RNA sequencing was first used to detect genes with higher expression in specific histological subtypes and metastatic and nonmetastatic tumors than in adjacent lung tissue. The diagnostic potential of the biomarkers was assessed using immunohistochemistry. Through gene expression analysis, This study confirms that HSP90 has a prognostic role in PC tumors and that inhibition of HSP90 may possess therapeutic potential in the management of PC tumor patients in the future.

Sections du résumé

Background UNASSIGNED
Pulmonary carcinoids (PCs) are rare tumors that account for <2% of all lung cancer cases. Patients who undergo resection for PC tumors generally have a favorable prognosis, but there is a risk for late recurrence and distant metastasis. The objective of this study was to identify biomarkers for PC tumors using RNA sequencing and immunohistochemistry.
Methods UNASSIGNED
A total of 128 formalin-fixed, paraffin-embedded PC tumor samples from patients surgically treated at Helsinki University Hospital between 1990 and 2013 were analyzed in the study. RNA sequencing was first used to detect genes with higher expression in specific histological subtypes and metastatic and nonmetastatic tumors than in adjacent lung tissue. The diagnostic potential of the biomarkers was assessed using immunohistochemistry.
Results UNASSIGNED
Through gene expression analysis,
Conclusions UNASSIGNED
This study confirms that HSP90 has a prognostic role in PC tumors and that inhibition of HSP90 may possess therapeutic potential in the management of PC tumor patients in the future.

Identifiants

pubmed: 37854156
doi: 10.21037/tlcr-23-304
pii: tlcr-12-09-1876
pmc: PMC10579826
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1876-1886

Informations de copyright

2023 Translational Lung Cancer Research. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-304/coif). The authors have no conflicts of interest to declare.

Références

Int J Oncol. 2019 Dec;55(6):1287-1295
pubmed: 31638190
Anticancer Res. 2018 Mar;38(3):1551-1562
pubmed: 29491085
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Genomics. 2005 Dec;86(6):627-37
pubmed: 16269234
Ann Oncol. 2021 Apr;32(4):439-451
pubmed: 33482246
Endocr Relat Cancer. 2010 Jun 25;17(3):623-36
pubmed: 20385747
Cancer Biol Ther. 2020 Jun 2;21(6):477-485
pubmed: 32228356
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):980-990
pubmed: 31912256
Trends Biochem Sci. 2006 Jul;31(7):395-401
pubmed: 16716593
Int J Mol Sci. 2018 Aug 29;19(9):
pubmed: 30158430
Lung. 2017 Dec;195(6):789-798
pubmed: 29022070
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Recent Pat Anticancer Drug Discov. 2017;12(1):35-47
pubmed: 27809750
Ann Thorac Surg. 2018 Oct;106(4):981-988
pubmed: 29908980
Cells. 2022 Sep 06;11(18):
pubmed: 36139353
Sci Rep. 2020 Apr 3;10(1):5923
pubmed: 32246062
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Thorac Oncol. 2020 Oct;15(10):1577-1598
pubmed: 32663527
Oncol Rep. 2023 Jan;49(1):
pubmed: 36367182
Int J Mol Sci. 2021 Apr 18;22(8):
pubmed: 33919591
Acta Oncol. 2018 Aug;57(8):1109-1116
pubmed: 29463166
Surg Oncol. 2020 Dec;35:460-465
pubmed: 33080545
Adv Cancer Res. 2016;129:1-30
pubmed: 26915999
Mod Pathol. 2016 Jun;29(6):616-29
pubmed: 26965582
Int J Oncol. 2012 May;40(5):1659-67
pubmed: 22246317
Endocr Relat Cancer. 2019 Feb 1;26(4):437-449
pubmed: 30730850

Auteurs

Jenni Niinimäki (J)

Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Harri Sihto (H)

Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Johanna Arola (J)

HUS Diagnostic Center, HUSLAB, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tiina Vesterinen (T)

HUS Diagnostic Center, HUSLAB, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Classifications MeSH